Novel synthetic scaffolds, including multifunctional compounds like LASSBio-1911, are being developed to balance potency, selectivity, and CNS accessibility, aiming to overcome the limitations of traditional HDAC inhibitors for neurodegenerative disease treatment. The gene discussed is HDAC9; the disease is neurodegenerative disease.